68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in
positron-emission tomography (PET) imaging. If this works, prostate cancer treatments can be
prescribed that match the location of the disease. PSMA is radiolabeled with Gallium-68
(Ga-68). This means a participant receives a small dose of radiation from the drug - less
than the annual radiation limit for a medical worker.
To test this new drug, participants will receive an injection of Ga-68 PSMA and then have a
PET scan. This PET scan, and the reported results, will be entered into the medical record
and shared with the treating oncologists.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Michael Graham PhD, MD
Collaborators:
Holden Comprehensive Cancer Center University of Iowa